LQDA VS ALLO Stock Comparison

Performance

LQDA
100/100

LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.

ALLO
10/100

ALLO returned -75.10% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

LQDA
88/100

4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.

ALLO
75/100

4 analysts offer 12-month price targets for ALLO. Together, they have an average target of 34.25, the most optimistic target put ALLO at 55 within 12-months and the most pessimistic has ALLO at 11.

Sentiment

LQDA
68/100

LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.

ALLO
70/100

ALLO had a bullish sentiment score of 70.27% across Twitter and StockTwits over the last 12 months. It had an average of 14.87 posts, 5.98 comments, and 19.98 likes per day.

Technicals

LQDA
29/100

LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

ALLO
11/100

ALLO receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

LQDA
10/100

LQDA has missed earnings 11 times in the last 20 quarters.

ALLO
54/100

ALLO has missed earnings 2 times in the last 20 quarters.

Profit

LQDA
10/100

Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ALLO
10/100

Out of the last 20 quarters, ALLO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

LQDA
48/100

LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

ALLO
43/100

ALLO has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Liquidia Corporation Common Stock Summary

Nasdaq / LQDA

Healthcare

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Allogene Therapeutics, Inc. Common Stock Summary

Nasdaq / ALLO

Healthcare

Biotechnology

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Power up your portfolio